<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30916127</article-id><article-id pub-id-type="pmc">6436787</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Previous Cardiac Surgery: a Predictor of Mortality in Aortic Valve
Replacement?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5470-0585</contrib-id><name><surname>Dayan</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD, FACC</role></contrib><contrib contrib-type="author"><name><surname>Arocena</surname><given-names>Maria Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Fernandez</surname><given-names>Amparo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Elo&#x000ed;sa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Zerpa</surname><given-names>Diego P&#x000e9;rez</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1">
<label>1</label> Instituto Nacional de Cirug&#x000ed;a Card&#x000ed;aca.
Montevideo, Uruguay. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: <bold>Victor Dayan</bold>,
https://orcid.org/0000-0002-5470-0585, Instituto Nacional de Cirurgia
Card&#x000ed;aca, 26 de Marzo 3459/602 - Montevideo, Uruguay. E-mail:
<email>victor_dayan@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2019</year></pub-date><volume>34</volume><issue>2</issue><fpage>173</fpage><lpage>178</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Previous cardiac surgery (PCS) is a risk factor for operative mortality in
pa-tients undergoing reoperative aortic valve replacement (AVR) and may be
influenced by the volume of patients in each center. The aim of this study
was to evaluate the results of AVR in patients with previous cardiac surgery
in a low volume cardiac center (400 cases per year).</p></sec><sec><title>Methods</title><p>Between January 2006 and December 2016, 854 patients underwent isolated AVR
surgery at our institution. Of these, 70 had PCS. Propensity match (PM) was
per-formed to balance basal covariates. Operative mortality and survival
were the primary outcomes.</p></sec><sec><title>Results</title><p>The PCS and first-time surgery (FTS) groups had significant differences in
base-line characteristics (PCS group were older, higher incidence of
hypertension, endocarditis, NYHA III/IV, lower LVEF, higher creatinine and
higher EuroSCORE). In the unmatched population, patients with PCS had higher
operative mortality (17.1% <italic>vs</italic>. 4.6%,
<italic>P</italic>=0.001). In the PM groups, this difference was not
significant (12.5% and 3.6%, <italic>P</italic>=0.08). The only independent
predictors for operative mortality found in the PCS group were age and
fe-male gender. Age and diabetes were identified as the only independent
predictors of sur-vival.</p></sec><sec><title>Conclusion</title><p>PCS was not a predictor for operative mortality nor long-term survival in
pa-tients undergoing isolated aortic valve replacement.</p></sec></abstract><kwd-group><kwd>Previous Cardiac Surgery</kwd><kwd>Aortic Valve Replacement</kwd><kwd>Mortality</kwd><kwd>Survival</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive Care Unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
replacement</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AXC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic cross-clamp</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association Functional Class</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Previous cardiac
surgery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Pacemaker</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FTS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= First time surgery</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">STS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society for Thoracic
Surgeons</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HC FMUSP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hospital das
Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o
Paulo</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transcatheter aortic
valve replacement</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HRs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hazard ratios</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VIVID</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Valve in Valve
International Data Registry</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Previous cardiac surgery (PCS) has been considered a predictor for adverse outcomes
in patients undergoing aortic valve replacement (AVR). This may be due to the higher
risk profile of patients that are submitted to a second surgery compared to those
with first time surgery (FTS) and that the technique for reoperation is generally
more demanding<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Reoperation, either in patients with previous
prosthetic valve replacement<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> or
coronary artery bypass grafting (CABG)<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>have not proven to be risk factors for operative mortality in
re-do AVR<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Nonetheless, PCS is
regarded as a risk factor for operative mortality in mortality scores such as
EuroSCORE and STS.</p><p>Decisions during first time surgery such as type of prosthesis or treatment of
minimally diseased valves at the time of CABG may be influenced by the potential
risk of a subsequent cardiac surgery<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The potential risk of a reoperation for AVR is one of the main
arguments for performing TAVR<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Operative mortality has been shown to be very similar in patients undergoing first
time and redo AVR<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Nonetheless,
most of these data come from big centers with high volume of cases performed by
surgeons with high level of expertise. Little data has been published regarding the
risk of previous cardiac surgery in low volume centers which are the most frequent
scenarios in South America.</p><p>The aim of this study was to evaluate the results of aortic valve replacement in
patients with PCS in a low volume institution which performs 400 cases per year.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Patients who underwent isolated AVR from January 2006 until December 2016 were
selected from our institution database. Urgent and emergency cases were
excluded.</p><p>Included patients were divided according to PCS or FST. Basal and operative variables
were extracted.</p><p>Propensity matching (PM) was used to balance the covariates. The following covariates
were included in the propensity match: age, logistic EuroSCORE (European System for
Cardiac Operative Risk Evaluation), body mass index, gender, pulmonary disease,
neurologic disease, renal disease, hypertension, left main stem disease, diabetes,
left ventricular ejection fraction (LVEF), New York Heart Association
classification, previous myocardial infarction, endocarditis, creatinine. Propensity
score for PCS was estimated by logistic regression. Variables included in the PM
were chosen by clinical relevance. The treated observations were matched in a 1:1
ratio using the nearest-neighbor method with a caliper width of 0.1 of the standard
deviation of the propensity score logit. Despite sequential modeling, EuroSCORE
remained unbalanced so this variable was incorporated in the multivariable
analysis.</p><p>Operative mortality was defined as death within 30 days of surgery or after 30 days
during the same hospitalization subsequent to the operation. PCS was defined as any
type of surgical procedure that required opening of the pericardium. PCS as a
predictor of operative mortality was evaluated using logistic regression analysis in
the propensity matched population. Regression analysis was also performed in the PCS
group to identify predictors of operative mortality in this group of patients.</p><p>Kaplan-Meier survival curves were plotted for the matched and tested using a log-rank
test. To analyze the association between risk factors and survival among the
propensity-matched cohorts, each covariate was tested for prediction using a Cox
proportional hazards. All covariates with a <italic>P</italic> &#x02264; 0.1 as well
as those unbalanced were included in the multivariate model. Hazard ratios (HRs)
were calculated for each variable.</p></sec><sec sec-type="results"><title>RESULTS</title><p>During the analyzed period, 854 (70 patients with PCS) patients underwent isolated
AVR at our institution. Patients with PCS were older, displayed higher incidence of
hypertension, endocarditis, NYHA III/IV, lower LVEF, higher creatinine and higher
euroSCORE (<xref rid="t1" ref-type="table">Table 1</xref>). Patients with PCS had
higher operative mortality (17.1% <italic>vs</italic>. 5.2%,
<italic>P</italic>&#x0003c;0.001) and postoperative bleeding (761&#x000b1;851ml
<italic>vs</italic>. 661&#x000b1;766ml, <italic>P</italic>=0.3) (<xref rid="t1" ref-type="table">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical variables of the overall population (n=854).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Previous surgery (70)</th><th align="center" rowspan="1" colspan="1">First surgery (784)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years, SD)</td><td align="center" rowspan="1" colspan="1">62.3 (15.1)</td><td align="center" rowspan="1" colspan="1">67.1 (13.4)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Female (%)</td><td align="center" rowspan="1" colspan="1">27 (38.6)</td><td align="center" rowspan="1" colspan="1">368 (46.9)</td><td align="center" rowspan="1" colspan="1">0.179</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (%)</td><td align="center" rowspan="1" colspan="1">17 (24.3)</td><td align="center" rowspan="1" colspan="1">176 (22.4)</td><td align="center" rowspan="1" colspan="1">0.741</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes (%)</td><td align="center" rowspan="1" colspan="1">19 (27.1)</td><td align="center" rowspan="1" colspan="1">137 (17.5)</td><td align="center" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" rowspan="1" colspan="1">43 (61.4)</td><td align="center" rowspan="1" colspan="1">541 (69.0)</td><td align="center" rowspan="1" colspan="1">0.191</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke (%)</td><td align="center" rowspan="1" colspan="1">3 (4.3)</td><td align="center" rowspan="1" colspan="1">23 (2.9)</td><td align="center" rowspan="1" colspan="1">0.347</td></tr><tr><td align="left" rowspan="1" colspan="1">Endocarditis (%)</td><td align="center" rowspan="1" colspan="1">10 (14.3)</td><td align="center" rowspan="1" colspan="1">34 (4.3)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial Fibrillation (%)</td><td align="center" rowspan="1" colspan="1">7 (10.0)</td><td align="center" rowspan="1" colspan="1">37 (4.7)</td><td align="center" rowspan="1" colspan="1">0.061</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA III/IV (%)</td><td align="center" rowspan="1" colspan="1">28 (40.0)</td><td align="center" rowspan="1" colspan="1">277 (35.3)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">52.3 (14.6)</td><td align="center" rowspan="1" colspan="1">57.0 (10.6)</td><td align="center" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.28 (1.04)</td><td align="center" rowspan="1" colspan="1">1.03 (0.58)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">AXC (min)</td><td align="center" rowspan="1" colspan="1">74.1 (24.6)</td><td align="center" rowspan="1" colspan="1">61.4 (18.7)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB (min)</td><td align="center" rowspan="1" colspan="1">116.4 (46.2)</td><td align="center" rowspan="1" colspan="1">85.3 (29.6)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bleeding (ml)</td><td align="center" rowspan="1" colspan="1">761 (851)</td><td align="center" rowspan="1" colspan="1">661 (766)</td><td align="center" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative stroke (%)</td><td align="center" rowspan="1" colspan="1">2 (2.9)</td><td align="center" rowspan="1" colspan="1">12 (1.5)</td><td align="center" rowspan="1" colspan="1">0.148</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative AF (%)</td><td align="center" rowspan="1" colspan="1">14 (20.0)</td><td align="center" rowspan="1" colspan="1">242 (30.9)</td><td align="center" rowspan="1" colspan="1">0.057</td></tr><tr><td align="left" rowspan="1" colspan="1">Permanent PM (%)</td><td align="center" rowspan="1" colspan="1">3 (4.3)</td><td align="center" rowspan="1" colspan="1">46 (5.9)</td><td align="center" rowspan="1" colspan="1">0.666</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days, SD)</td><td align="center" rowspan="1" colspan="1">3.1 (3.2)</td><td align="center" rowspan="1" colspan="1">2.6 (3.9)</td><td align="center" rowspan="1" colspan="1">0.395</td></tr><tr><td align="left" rowspan="1" colspan="1">euroSCORE (SD)</td><td align="center" rowspan="1" colspan="1">16.4 (13.4)</td><td align="center" rowspan="1" colspan="1">6.7 (6.2)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Operative mortality (%)</td><td align="center" rowspan="1" colspan="1">12 (17.1)</td><td align="center" rowspan="1" colspan="1">41 (5.2)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AF=atrial fibrillation; AXC=aortic cross-clamp; CABG=coronary artery
bypass grafting; CPB=cardiopulmonary bypass; ICU=Intensive Care Unit;
LVEF=left ventricular ejection fraction; NYHA=New York Heart Association
Functional Class; PM=pacemaker</p></fn></table-wrap-foot></table-wrap><p>PM rendered 112 patients with similar baseline characteristics except for higher
incidence of endocarditis, atrial fibrillation and EuroSCORE in the PCS group which
were adjusted by logistic regression analysis (<xref rid="t2" ref-type="table">Table
2</xref>). In the matched population, operative mortality was similar in PCS and
FST surgery groups (12.5% <italic>vs</italic>. 3.6%, <italic>P</italic>=0.08) (<xref rid="t2" ref-type="table">Table 2</xref>). AXC, CPB time and ICU stay were
significantly higher in the PCS group.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical variables of the propensity matched population (n=112).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Re-do (56)</th><th align="center" rowspan="1" colspan="1">First surgery (56)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years, SD)</td><td align="center" rowspan="1" colspan="1">63.1 (14.5)</td><td align="center" rowspan="1" colspan="1">67.7 (14.9)</td><td align="center" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" rowspan="1" colspan="1">Female (%)</td><td align="center" rowspan="1" colspan="1">22 (39.3)</td><td align="center" rowspan="1" colspan="1">25 (44.6)</td><td align="center" rowspan="1" colspan="1">0.566</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (%)</td><td align="center" rowspan="1" colspan="1">14 (25.0)</td><td align="center" rowspan="1" colspan="1">8 (14.3)</td><td align="center" rowspan="1" colspan="1">0.154</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes (%)</td><td align="center" rowspan="1" colspan="1">12 (21.4)</td><td align="center" rowspan="1" colspan="1">7 (12.5)</td><td align="center" rowspan="1" colspan="1">0.208</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" rowspan="1" colspan="1">33 (58.9)</td><td align="center" rowspan="1" colspan="1">38 (67.9)</td><td align="center" rowspan="1" colspan="1">0.327</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke (%)</td><td align="center" rowspan="1" colspan="1">2 (3.6)</td><td align="center" rowspan="1" colspan="1">2 (3.6)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Endocarditis (%)</td><td align="center" rowspan="1" colspan="1">5 (8.9)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial Fibrillation (%)</td><td align="center" rowspan="1" colspan="1">6 (10.7)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA III/IV (%)</td><td align="center" rowspan="1" colspan="1">18 (32.2)</td><td align="center" rowspan="1" colspan="1">23 (41.1)</td><td align="center" rowspan="1" colspan="1">0.534</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">52.5 (14.5)</td><td align="center" rowspan="1" colspan="1">53.5 (13.3)</td><td align="center" rowspan="1" colspan="1">0.719</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.15 (0.53)</td><td align="center" rowspan="1" colspan="1">1.02 (0.35)</td><td align="center" rowspan="1" colspan="1">0.107</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG (%)</td><td align="center" rowspan="1" colspan="1">18 (32.1)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous valve surgery (%)</td><td align="center" rowspan="1" colspan="1">25 (44.6)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous aortic surgery (%)</td><td align="center" rowspan="1" colspan="1">4 (7.1)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous congenital surgery (%)</td><td align="center" rowspan="1" colspan="1">8 (14.3)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Other previous surgery (%)</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">AXC (min)</td><td align="center" rowspan="1" colspan="1">72.6 (23.1)</td><td align="center" rowspan="1" colspan="1">42.5 (10.3)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB (min)</td><td align="center" rowspan="1" colspan="1">112.1 (44.2)</td><td align="center" rowspan="1" colspan="1">68.8 (19.4)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Bioprosthesis</td><td align="center" rowspan="1" colspan="1">35 (62.5)</td><td align="center" rowspan="1" colspan="1">46 (82.1)</td><td align="center" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bleeding (ml)</td><td align="center" rowspan="1" colspan="1">867 (898)</td><td align="center" rowspan="1" colspan="1">649 (620)</td><td align="center" rowspan="1" colspan="1">0.140</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative stroke (%)</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">2 (3.6)</td><td align="center" rowspan="1" colspan="1">0.558</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative AF (%)</td><td align="center" rowspan="1" colspan="1">14 (25.0)</td><td align="center" rowspan="1" colspan="1">16 (28.6)</td><td align="center" rowspan="1" colspan="1">0.670</td></tr><tr><td align="left" rowspan="1" colspan="1">Permanent PM (%)</td><td align="center" rowspan="1" colspan="1">2 (3.6)</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">0.558</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (days, SD)</td><td align="center" rowspan="1" colspan="1">3.3 (3.2)</td><td align="center" rowspan="1" colspan="1">2.3 (1.6)</td><td align="center" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE (SD)</td><td align="center" rowspan="1" colspan="1">15.1 (12.1)</td><td align="center" rowspan="1" colspan="1">6.4 (4.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Operative mortality (%)</td><td align="center" rowspan="1" colspan="1">7 (12.5)</td><td align="center" rowspan="1" colspan="1">2 (3.6)</td><td align="center" rowspan="1" colspan="1">0.082</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AF=atrial fibrillation; AXC=aortic cross-clamp; CABG=coronary artery
bypass grafting; CPB=cardiopulmonary bypass; ICU=intensive care unit;
LVEF=left ventricular ejection fraction; NYHA=New York Heart Association
Functional Class; PM=pacemaker</p></fn></table-wrap-foot></table-wrap><p>After adjusting for baseline differences in the PM population, PCS was not an
independent predictor for operative mortality.</p><p>Predictors for operative mortality were evaluated in patients with PCS (<xref rid="t3" ref-type="table">Table 3</xref>). The only independent predictors in
this group of patients were age and female gender. Type of previous surgery (CABG or
valve replacement) was not a predictor for operative mortality.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Independent predictors for operative mortality in previous cardiac surgery
patients undergoing aortic valve replacement (n=70).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">OR (95%CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.15 (1.03-1.28)</td><td align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">8.5 (1.1-66.7)</td><td align="center" rowspan="1" colspan="1">0.041</td></tr></tbody></table></table-wrap><p>Among the PM population, survival was significantly lower in the PCS group (6.52
&#x000b1; 0.72 years <italic>vs</italic>. 8.72 &#x000b1; 0.3 years,
<italic>P</italic>=0.013) (<xref ref-type="fig" rid="f1">Figure 1</xref>).
Nonetheless, after multivariate Cox regression analysis, age and diabetes were the
only independent predictors of survival (<xref rid="t4" ref-type="table">Table
4</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Survival in the matched population.</p></caption><graphic xlink:href="rbccv-34-02-0173-g01"/></fig>
</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Independent predictors for survival in propensity matched patients with
isolated aortic valve replacement (n=140).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">HR (95%CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.07 (1.01-1.12)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">2.78 (1.03-7.51)</td><td align="center" rowspan="1" colspan="1">0.045</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This study demonstrates that PCS is not a predictor for operative mortality nor
long-term survival in propensity matched patients undergoing isolated AVR. The only
independent predictors for survival in PM patients undergoing isolated AVR were age
and diabetes.</p><p>Analysis of the overall population showed that patients with PCS were younger but
with more risk factors such as diabetes, worse LVEF, higher incidence of
endocarditis, worse NYHA class and higher preoperative creatininemia. The higher
risk profile of these patients is reflected by their higher EuroSCORE compared with
patients undergoing first time AVR.</p><p>It is well known that reoperation is a highly demanding procedure performed in sicker
patients which requires high surgical expertise<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Therefore, we believe that smaller cardiac surgery centers
should rely on results provided by similar centers instead of underestimating the
operative mortality of these procedures based on published results from high volume
centers. Results from big surgical centers such as the Mayo Clinic, report low
operative mortality in previous AVR patients and therefore conclude that
bioprosthesis should be encouraged in younger patients<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In their study, the authors do not specify the
surgical risk score (EuroSCORE or STS score) of their population nor the inclusion
of patients who had previous CABG in the reoperative AVR group. These data are very
important in order to define the real surgical risk of the reoperative group. Even
though our center has a limited number of redo cases per year, operative mortality
in the entire cohort was similar to larger regional cardiac centers<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Pomerantzeff et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> at InCor HC FMUSP report 18%
operative mortality in their entire redo aortic valve replacement group which is
quite similar to our data. In the PM cohort, the re-do group had a higher risk mean
EuroSCORE with a predicted operative mortality of 12%. The observed operative
mortality of our previous surgery and first-time propensity matched groups was
similar to the predicted EuroSCORE. Therefore, results from our center reflect
appropriate standard of care and have external validity implications.</p><p>We analyzed specifically the predictors for operative mortality in patients with PCS.
The only independent predictors after multivariate analysis were age and gender.
Jamieson et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> published
similar findings regarding the risk of female gender in this group of patients.
Although we were not able to demonstrate it due to our low number of patients, we
believe that the use of smaller prosthesis and hence higher risk of severe
patient-prosthesis mismatch in female patients could explain the higher operative
mortality. Lytle et al have shown similar operative mortality results as our group
and have established as well, age and female gender as independent predictors of
mortality<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Reoperative aortic valve replacement requires to be performed by trained surgeons.
Difficulty in these procedures lie on the risk of damaging anatomical structures
during chest re-entering or dissection of pericardial adhesions. Furthermore, these
patients have higher risk of permanent pacemaker due to complications associated
with prosthesis explantation<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.
Nonetheless, our results show very low incidence of pacemaker requirement, which was
similar to the primary AVR group.</p><p>Long-term survival is lower in patients with PCS probably due to their higher risk
profile and not to the re-operation procedure. After adjusting for these
comorbidities, predictors for long-term survival were similar to major
cardiovascular risk factors: age and diabetes. Therefore, patients who survive the
surgical procedure depend on the adequate control of their risk factors to ensure
long-term survival.</p><p>This data should encourage careful decision-making as to whether choosing to operate
on patients with a PCS, and considering other less invasive therapeutic options if
indicated, such as TAVR<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. The
VIVID (Valve in Valve International Data Registry) registry has reported 1-year
survival of 83.2% in patients who received a TAVR for aortic bioprosthesis
degeneration<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>which is
similar to our 1 year survival in the PCS group (80.3%). Predictors for higher
1-year mortality in the VIVID registry were small aortic bioprosthesis (&#x02264;
21mm) and aortic stenosis.</p><p>This study suffers from a number of limitations, including the heterogeneity of the
study group, the relatively small sample size (total sample size 854 patients, with
70 patients in the reoperation group) and the limitations inherent to the
retrospective nature of the analysis. Although PM was performed to correct for these
differences, selection bias is inherently introduced due to the sample
characteristics. The volume of cardiac surgeries performed in our institution, which
is around 400 per year, may also influence the results.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Higher comorbidities in patients with PCS explain the higher risk for operative
mortality and long-term survival in reoperation for AVR. Nonetheless, in PM
patients, PCS is not predictor for operative mortality nor long-term survival. Our
results show that re-do AVR may be safely performed in a low volume cardiac surgery
center.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VD</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MJA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AF</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important in-tellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ES</td><td align="left" valign="top" rowspan="1" colspan="1"> Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for im-portant intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DPZ</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important in-tellectual content; final approval of
the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Instituto Nacional de Cirug&#x000ed;a
Card&#x000ed;aca. Montevideo, Uruguay.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Moon</surname><given-names>MR</given-names></name></person-group><article-title>Reoperative Aortic Valve Replacement After Previous Coronary
Artery Bypass Grafting or Aortic Valve Replacement</article-title><source>Oper Tech Thorac Cardiovasc Surg</source><year>2014</year><volume>19</volume><issue>4</issue><fpage>482</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1053/j.optechstcvs.2015.04.001</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>IM</given-names></name><name><surname>Piegas</surname><given-names>LS</given-names></name><name><surname>Mattos</surname><given-names>LAP</given-names></name><name><surname>Tanajura</surname><given-names>LF</given-names></name><name><surname>Egito</surname><given-names>ET</given-names></name><name><surname>Abdulmassih Neto</surname><given-names>C</given-names></name><etal/></person-group><article-title>Reopera&#x000e7;&#x000e3;o em pacientes
revascularizados</article-title><source>Rev Bras Circ Cardio-vasc</source><year>1987</year><volume>2</volume><issue>3</issue><fpage>171</fpage><lpage>174</lpage></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potter</surname><given-names>DD</given-names></name><name><surname>Sundt 3rd</surname><given-names>TM</given-names></name><name><surname>Zehr</surname><given-names>KJ</given-names></name><name><surname>Dearani</surname><given-names>JA</given-names></name><name><surname>Daly</surname><given-names>RC</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Operative risk of reoperative aortic valve
replacement</article-title><source>J Thorac Cardiovasc Surg</source><month>1</month><year>2005</year><volume>129</volume><issue>1</issue><fpage>94</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">15632830</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundt III</surname><given-names>TM</given-names></name><name><surname>Murphy</surname><given-names>SF</given-names></name><name><surname>Barzilai</surname><given-names>B</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>Mendeloff</surname><given-names>EN</given-names></name><name><surname>Huddleston</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Previous Coronary Artery Bypass Grafting Is Not a Risk Factor for
Aortic Valve Replace-ment</article-title><source>Ann Thorac Surg</source><year>1997</year><volume>64</volume><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">9307452</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davierwala</surname><given-names>PM</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name><name><surname>David</surname><given-names>TE</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Maganti</surname><given-names>M</given-names></name><name><surname>Yau</surname><given-names>TM</given-names></name></person-group><article-title>Reoperation is not an independent predictor of mortality during
aortic valve surgery</article-title><source>J Thorac Cardiovasc Surg</source><month>2</month><year>2006</year><volume>131</volume><issue>2</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">16434261</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akins</surname><given-names>CW</given-names></name><name><surname>Hilgenberg</surname><given-names>AD</given-names></name><name><surname>Vlahakes</surname><given-names>GJ</given-names></name><name><surname>Madsen</surname><given-names>JC</given-names></name><name><surname>MacGillivray</surname><given-names>TE</given-names></name></person-group><article-title>Aortic valve re-placement in patients with previous cardiac
surgery</article-title><source>J Card Surg</source><season>Jul-Aug</season><year>2004</year><volume>19</volume><issue>4</issue><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">15245459</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onorati</surname><given-names>F</given-names></name><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>De Feo</surname><given-names>M</given-names></name><name><surname>Mariscalco</surname><given-names>G</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Santarpino</surname><given-names>G</given-names></name><etal/></person-group><article-title>Mid-term results of aortic valve surgery in redo scenarios in the
current practice: results from the mul-ticentre European RECORD (REdo
Cardiac Operation Research Database) initiative&#x02020;</article-title><source>Eur J Cardiothorac Surg</source><month>2</month><year>2015</year><volume>47</volume><issue>2</issue><fpage>269</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezu116</pub-id><pub-id pub-id-type="pmid">24686001</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomerantzeff</surname><given-names>PM</given-names></name><name><surname>Yochitomi</surname><given-names>Y</given-names></name><name><surname>Fabri</surname><given-names>HA</given-names></name><name><surname>Cardoso</surname><given-names>LF</given-names></name><name><surname>Tarasoutchi</surname><given-names>F</given-names></name><name><surname>Max</surname><given-names>Grinberg</given-names></name><etal/></person-group><article-title>Reopera&#x000e7;&#x000f5;es valvares: experi&#x000ea;ncia do
InC&#x000f3;r-FMUSP</article-title><source>Braz J Cardiovasc Surg</source><year>1991</year><volume>6</volume><fpage>182</fpage><lpage>189</lpage></element-citation></ref><ref id="r9"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>WR</given-names></name><name><surname>Burr</surname><given-names>LH</given-names></name><name><surname>Miyagishima</surname><given-names>RT</given-names></name><name><surname>Janusz</surname><given-names>MT</given-names></name><name><surname>Fradet</surname><given-names>GJ</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Lichtenstein</surname><given-names>SV</given-names></name></person-group><article-title>Re-operation for bioprosthetic aortic structural failure - risk
assessment</article-title><source>Eur J Cardiothorac Surg</source><month>12</month><year>2003</year><volume>24</volume><issue>6</issue><fpage>873</fpage><lpage>878</lpage><pub-id pub-id-type="pmid">14643803</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Cosgrove</surname><given-names>DM</given-names></name><name><surname>Taylor</surname><given-names>PC</given-names></name><name><surname>Gill</surname><given-names>CC</given-names></name><name><surname>Goormastic</surname><given-names>M</given-names></name><name><surname>Golding</surname><given-names>LR</given-names></name><name><surname>Stewart</surname><given-names>RW</given-names></name><name><surname>Loop</surname><given-names>FD</given-names></name></person-group><article-title>Reoperations for valve surgery: perioperative mortality and
determinants of risk for 1,000 patients, 1958-1984</article-title><source>Ann Thorac Surg</source><month>12</month><year>1986</year><volume>42</volume><issue>6</issue><fpage>632</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">3491589</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaia</surname><given-names>DF</given-names></name><name><surname>Couto</surname><given-names>A</given-names></name><name><surname>Breda</surname><given-names>JR</given-names></name><name><surname>Ferreira</surname><given-names>CB</given-names></name><name><surname>Macedo</surname><given-names>MT</given-names></name><name><surname>Gimenes</surname><given-names>MV</given-names></name><name><surname>Buffolo</surname><given-names>E</given-names></name><name><surname>Palma</surname><given-names>JH</given-names></name></person-group><article-title>Transcatheter aortic valve-in-valve implantation: a selection
change?</article-title><source>Rev Bras Cir Cardio-vasc</source><season>Jul-Sep</season><year>2012</year><volume>27</volume><issue>3</issue><fpage>355</fpage><lpage>361</lpage><comment>English, Portuguese</comment></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvir</surname><given-names>D</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Bleiziffer</surname><given-names>S</given-names></name><name><surname>Pasic</surname><given-names>M</given-names></name><name><surname>Waksman</surname><given-names>R</given-names></name><name><surname>Kodali</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transcatheter aortic valve implantation in failed bioprosthetic
surgical valves</article-title><source>JAMA</source><month>7</month><year>2014</year><volume>312</volume><issue>2</issue><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.7246</pub-id><pub-id pub-id-type="pmid">25005653</pub-id></element-citation></ref></ref-list></back></article>